Revista clinica espanola · 2026
Benefits of a comprehensive care model in patients with heart failure and anemia: UMIPIC program.
СтатьяНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cerqueiro-González J M, Franco Á G, Bailón M M, Iborra P L, Martel A C, Pérez Silvestre J, Pérez-Barquero M M, Espinosa L M
Аннотация
OBJECTIVES: To evaluate the prognostic benefit of the UMIPIC care program in patients with heart failure (HF) and anemia.
METHODS: Data from 3,152 patients with HF and anemia from the RICA registry were analyzed. They were divided into two groups and selected by matched match: one receiving UMIPIC follow-up (UMIPIC group, N: 621) and the other receiving conventional care (non-UMIPIC group, N: 524). Admissions and mortality were assessed during 12 months of follow-up.
RESULTS: The UMIPIC group had a lower rate of admissions for HF (19.3% vs. 29.8%; p < 0.001) and a reduction in overall mortality (24.8% vs. 36.6%; p < 0.001). Patients in the UMIPIC group with associated iron deficiency (ID) also had a lower rate of admissions for HF (19.1% vs. 32.5%; p < 0.001).
CONCLUSIONS: Implementation of the UMIPIC program in patients with HF and anemia reduces admissions and overall mortality at one year. Additional studies are needed to explore the impact of specific ID treatment within these care program.
METHODS: Data from 3,152 patients with HF and anemia from the RICA registry were analyzed. They were divided into two groups and selected by matched match: one receiving UMIPIC follow-up (UMIPIC group, N: 621) and the other receiving conventional care (non-UMIPIC group, N: 524). Admissions and mortality were assessed during 12 months of follow-up.
RESULTS: The UMIPIC group had a lower rate of admissions for HF (19.3% vs. 29.8%; p < 0.001) and a reduction in overall mortality (24.8% vs. 36.6%; p < 0.001). Patients in the UMIPIC group with associated iron deficiency (ID) also had a lower rate of admissions for HF (19.1% vs. 32.5%; p < 0.001).
CONCLUSIONS: Implementation of the UMIPIC program in patients with HF and anemia reduces admissions and overall mortality at one year. Additional studies are needed to explore the impact of specific ID treatment within these care program.